Literature DB >> 24330593

Multiple mechanisms underlying the long duration of action of thienorphine, a novel partial opioid agonist for the treatment of addiction.

Gang Yu1, Shu-Hui Li, Meng-Xun Cui, Ling-Di Yan, Zheng Yong, Pei-Lan Zhou, Rui-Bin Su, Ze-Hui Gong.   

Abstract

AIMS: It is considered that a long-acting therapy would be advantageous in the treatment of addiction. In a search for novel buprenorphine analogues, thienorphine was demonstrated to be an extremely long-acting orally active partial opioid agonist. This study explored the mechanisms underlying the long-lasting effects of thienorphine.
METHODS: The binding kinetics of [(3) H]thienorphine were measured in membrane preparations expressing cloned rat opioid receptors. Flow cytometric analysis was used to determine the effect of thienorphine on the surface opioid receptor number. The long-lasting effects of thienorphine were also confirmed at the tissue level and in vivo.
RESULTS: At 37°C, [(3) H]thienorphine showed rapid association with μ- and κ-opioid receptors, while its dissociation was sluggish and biphasic (K-1 = 0.21 min(-1) , K-2 = 0.0078 min(-1) for the μ-receptor; K-1 = 0.17 min(-1) , K-2 = 0.0042 min(-1) for the κ-receptor). Treatment with thienorphine for 24, 48, and 72 h downregulated surface μ-receptor in a dose- and time-dependent manner. The inhibitory effect of thienorphine on guinea pig ileum persisted for more than 120 min after prolonged washing. In vivo, thienorphine exhibited significant antagonism of morphine-induced antinociception for more than 7 days.
CONCLUSIONS: These results indicate that multiple factors, including persistent receptor occupation and enhanced receptor downregulation, may contribute to the long-lasting effects of thienorphine that would be beneficial for its application in addiction treatment.
© 2013 John Wiley & Sons Ltd.

Entities:  

Keywords:  Kinetics; Long duration of action; Opioid receptor; Surface receptor number; Thienorphine

Mesh:

Substances:

Year:  2013        PMID: 24330593      PMCID: PMC6492997          DOI: 10.1111/cns.12210

Source DB:  PubMed          Journal:  CNS Neurosci Ther        ISSN: 1755-5930            Impact factor:   5.243


  26 in total

1.  Ligand-induced changes in surface mu-opioid receptor number: relationship to G protein activation?

Authors:  P A Zaki; D E Keith; G A Brine; F I Carroll; C J Evans
Journal:  J Pharmacol Exp Ther       Date:  2000-03       Impact factor: 4.030

2.  Thienorphine: receptor binding and behavioral effects in rhesus monkeys.

Authors:  Jun-Xu Li; Ginger L Becker; John R Traynor; Ze-Hui Gong; Charles P France
Journal:  J Pharmacol Exp Ther       Date:  2007-01-12       Impact factor: 4.030

Review 3.  Relapse and relapse prevention.

Authors:  Thomas H Brandon; Jennifer Irvin Vidrine; Erika B Litvin
Journal:  Annu Rev Clin Psychol       Date:  2007       Impact factor: 18.561

4.  Thienorphine is a potent long-acting partial opioid agonist: a comparative study with buprenorphine.

Authors:  Gang Yu; Yong-Juan Yue; Meng-Xun Cui; Ze-Hui Gong
Journal:  J Pharmacol Exp Ther       Date:  2006-03-28       Impact factor: 4.030

5.  Continuous opioid agonist treatment dose-dependently regulates mu-opioid receptors and dynamin-2 in mouse spinal cord.

Authors:  Qiuyu Zhang; Vishal Purohit; Byron C Yoburn
Journal:  Synapse       Date:  2005-06-01       Impact factor: 2.562

6.  BU74, a complex oripavine derivative with potent kappa opioid receptor agonism and delayed opioid antagonism.

Authors:  Stephen M Husbands; Claire L Neilan; Jillian Broadbear; Peter Grundt; Simon Breeden; Mario D Aceto; James H Woods; John W Lewis; John R Traynor
Journal:  Eur J Pharmacol       Date:  2005-02-21       Impact factor: 4.432

7.  mu-Opioid receptor downregulation contributes to opioid tolerance in vivo.

Authors:  K Stafford; A B Gomes; J Shen; B C Yoburn
Journal:  Pharmacol Biochem Behav       Date:  2001 May-Jun       Impact factor: 3.533

8.  Internalization and down-regulation of mu opioid receptors by endomorphins and morphine in SH-SY5Y human neuroblastoma cells.

Authors:  Kristen A Horner; James E Zadina
Journal:  Brain Res       Date:  2004-12-03       Impact factor: 3.252

9.  Characterization of the complex morphinan derivative BU72 as a high efficacy, long-lasting mu-opioid receptor agonist.

Authors:  Claire L Neilan; Stephen M Husbands; Simon Breeden; M C Holden Ko; Mario D Aceto; John W Lewis; James H Woods; John R Traynor
Journal:  Eur J Pharmacol       Date:  2004-09-19       Impact factor: 4.432

10.  Simultaneous determination of thienorphine and its active metabolite thienorphine glucuronide in rat plasma by liquid chromatography-tandem mass spectrometry and its application to pharmacokinetic studies.

Authors:  Qi Kong; Jianzhong Qiao; Xiaoying Wang; Shulan Yuan; Zhenqing Zhang; Zehui Gong; Jinxiu Ruan
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2007-09-29       Impact factor: 3.205

View more
  1 in total

1.  Inhibition of P-Glycoprotein and Multidrug Resistance-Associated Protein 2 Regulates the Hepatobiliary Excretion and Plasma Exposure of Thienorphine and Its Glucuronide Conjugate.

Authors:  Ling-Lei Kong; Guo-Lin Shen; Zhi-Yuan Wang; Xiao-Mei Zhuang; Wei-Bin Xiao; Mei Yuan; Ze-Hui Gong; Hua Li
Journal:  Front Pharmacol       Date:  2016-08-09       Impact factor: 5.810

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.